- Biomarkers for Lewy Body Dementias (U01) RFA-NS-16-022. The purpose of this FOA is to 1) expand the collection of clinical data and biological specimens in the NINDS Parkinson’s Disease Biomarkers Program (PDBP), a community research resource, to include data from patients with Lewy Body Dementias (including Dementia with Lewy Bodies and Parkinson's Disease with Dementia), and 2) to support hypothesis-driven clinical research to discover biomarkers that will improve the efficiency and outcome of Phase II clinical trials for the Lewy Body dementias and to provide an expansion of this existing research resource center for dissemination of information and access by the scientific community for further advancing research in this field. Applications may include both of these goals if justified. Letter of intent due: April 16, 2016; Application due: May 10, 2016. Contact: Deb Babcock, MD, PhD
- Biomarkers Discovery in Parkinsonism (U01) PAR-16-112. The purpose of this FOA is to support hypothesis-driven research to discover human biomarkers in Parkinson’s disease and other Parkinsonian syndromes, as a component of the NINDS Parkinson’s Disease Biomarkers Program (PDBP). This FOA encourages biomarkers discovery projects in 1) genetically causal Parkinson's disease, especially for particular sub-types of Parkinson's Disease (PD), including genetic cohorts, biologically defined cohorts of idiopathic PD, or ethnic subgroups of idiopathic PD; 2) The differentiation of synucleinopathies (such as PD and Multiple System Atrophy (MSA) from tauopathies (such as Progressive Supranuclear Palsy and Corticobasal degeneration); or 3) to improve diagnostic differentiation between idiopathic/subtypes of PD and these disorders, as well as from Essential tremor. In order to further advance research in this area, broad sharing of biospecimens and associated data is a critical feature of the PDBP generally and of this FOA specifically. A timeline including milestones, which will be used to evaluate the application not only in peer review but also in consideration of the awarded project for funding of non-competing award years, is required for all studies. Letter of intent due 30 days prior to application due date. Application Due: Sept 6, 2016; Sept 6, 2017; Sept 6, 2018. Contact: Katrina Gwinn, M.D
- Request to Access Parkinson's Disease Related-Biospecimens (X01) PAR-14-340. Applications to this X01 have a rolling submission. Submissions between Feb 16-April 15, 2016 have a review date by May 19, 2016; submissions between April 16-July 15, 2016 will be reviewed by August 18, 2016. Contact: Katrina Gwinn, M.D., Marg Sutherland, Ph.D.
- Parkinson's Disease Biomarker Program (PDBP) Discovery Projects (U01) PAR-NS-14-259. The purpose of this funding opportunity announcement (FOA) is to support up to three years of study for the discovery, assay optimization, and replication stages required for the development of biological biomarkers for Parkinson's disease (PD). Application receipt date: May 4, 2016, by 5:00 PM local time of applicant organization. Contact: Katrina Gwinn, M.D., Marg Sutherland, Ph.D